10 Jan 2023 Research

Clinical trial begins for pioneering new cancer treatment

This article has been updated in January 2023 after first being published on 26 April 2021.

A potentially ground-breaking new cancer treatment has entered clinical trials in the United States. Leukaemia UK funded researcher, Dr Konstantinos Tzelepis, led the research underpinning this cutting-edge trial. 

Dr Konstantinos Tzelepis was awarded a Leukaemia UK research fellowship in 2020. Our fellowships provide vital funding at a critical point to enable early career researchers with a passion for science, a desire to develop new ideas and translate scientific advances into clinical practice, to become established independent researchers and the leading blood cancer scientists of tomorrow.

Thanks to our support, Konstantinos’s research has led to the development of a new class of cancer drug with the potential to treat leukaemia and other aggressive cancers.

“This is the beginning of a new era for cancer therapeutics.” – Dr Konstantinos Tzelepis

In a study published in 2017, a collaborative effort between the Gurdon Institute at the University of Cambridge and the Wellcome Sanger Institute, showed how one such enzyme, METTL3, plays a key role in the development and maintenance of acute myeloid leukaemia. The enzyme becomes over-expressed – that is, over-produced – in certain cell types, leading to the disease.

In 2021, Dr Tzelepis, Professor Kouzarides and colleagues at the Wellcome Sanger Institute and STORM Therapeutics, identified a compound, STM2457, that can inhibit the action of METTL3.

Inhibitors of METTL3 have potential to be used to treat AML – a cancer of the blood in which bone marrow produces abnormal white blood cells. AML proceeds rapidly and aggressively, usually requiring immediate treatment, and affects both children and adults. Around 3,100 people are diagnosed with the condition every year in the UK, the majority of whom are over 65 years of age.

We spoke to Konstantinos about this break-through:

“This is the result of many years of research. And in this study, we’re particularly focused on developing a drug that is inhibiting a protein called METTL3. METTL3 is an enzyme that we found that is overrepresented in cancer cells versus normal.

METTL3 is a protein that we all have in our body, in most of the cells of our body, if not all of the cells. But in some of the cancers including AML, acute myeloid leukaemia, the cancerous cells, the leukaemia cells in particular, they actually have higher levels of this protein.

And this is how we prioritize this target compared to other targets that we have from the same protein family. And it actually paid off because we saw that under a certain level of blocking of this protein, this is devastating for the cancer cells, however, for the normal cells and especially for the STEM cells, as we show in the current study, the loss of this protein was, or the function of the protein was dispensable.”

Since these important 2021 results, STORM therapeutics have announced the start of a clinical trial of its candidate METTL3 inhibitor – STC-15 – the first time this type of drug has entered clinical development. In November 2022, the first patient was given STC-15 as part of the US-based trial. Details of the study can be found on clinicaltrials.gov under the identifier NCT05584111. Around 40-60 patients with solid tumours are due to be enrolled into the trial, which will focus primarily on the drug’s safety. Data from this study will inform future clinical trials which may include studies in AML.

Fiona Hazell, Leukaemia UK CEO said,

“We are delighted to be a part of this ground-breaking research. Not only has it established a new way of identifying potential drug targets, developing targeted treatments to select and destroy cancer cells but ultimately, could make a real difference to the lives of patients with AML.

Around 3,100 people each year are diagnosed with AML in the UK and treatments haven’t progressed for the past 30 years, so this research brings hope that patients diagnosed with AML will have more treatment options in the future.

We fund early career researchers for this exact reason, they have new, exciting ideas that translate scientific advances into clinical practice, giving patients hope and developing new treatments to stop leukaemia devastating lives.”

The research was supported by Wellcome, Cancer Research UK, the European Research Council, the Kay Kendall Leukaemia Fund, and Leukaemia UK.

Find out more about our funded research projects.

Photo credit (top): Jeff Moore

Related posts

Leading leukaemia charities call on Rishi Sunak not to cut financial lifeline for blood cancer patients

24 September 2021

Leading leukaemia charities call on Rishi Sunak not to cut financial lifeline for blood cancer patients

Leukaemia Care, Leukaemia UK and Leukaemia and Lymphoma Northern Ireland, have written to the Chancellor urging him to realise the devastating impact the end of the Coronavirus Job Retention Scheme will have on the clinically extremely vulnerable (CEV).

Leukaemia UK unveils an exciting new brand 

10 August 2022

Leukaemia UK unveils an exciting new brand 

Leukaemia UK has today revealed a bold new look and feel that embodies the charity’s ambitious new strategy and our desire to be a greater force for change.  Bringing together…

Non-existent awareness of leukaemia symptoms “extremely worrying” – say leading UK leukaemia charities, as they launch memorable new campaign to get people “parroting on” about the symptoms

24 August 2022

Non-existent awareness of leukaemia symptoms “extremely worrying” – say leading UK leukaemia charities, as they launch memorable new campaign to get people “parroting on” about the symptoms

People over 55 also underestimate their risk, thinking that leukaemia is a childhood disease. Only 11% of over 55s thought that they had the greatest risk of leukaemia[1], whereas in…

Lymphoma: Understanding relapse and treatment resistance

11 January 2019

Lymphoma: Understanding relapse and treatment resistance

Dr Dinis Calado, The Francis Crick Institute and Project Grant Holder